Loading news...
Citigroup Inc. lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 14.8% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 145,608 shares of the medical equipment provider's stock after selling 25,334 shares during the quarter. Citigroup Inc.
Company's Chief Movement Officer, Arnold Schwarzenegger,Will Be Presidential Guest Speaker WARSAW, Ind., Feb. 25, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced it will unveil new clinical and operational data and showcase its newest innovations at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting.
WARSAW, Ind., Feb. 23, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2026.
Partner Reed Kathrein Scrutinizing ZBH's "High Confidence" Assurances After 15% Stock Collapse and Reduced Revenue Guidance SAN FRANCISCO, Feb. 18, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (NYSE: ZBH) following a series of disclosures that calls into question the reasonable basis for the company's previously expressed "high confidence" in its 2025 revenue targets. The firm urges investors who suffered significant losses to submit your ZBH losses now.
ABN Amro Investment Solutions trimmed its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE: ZBH) by 31.6% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,860 shares of the medical equipment provider's stock after selling
More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable firms in the healthcare space can surprise with growth upon the release of a new blockbuster drug or medical device, and earnings periods are an opportunity for management to provide insight and commentary beyond what investors might expect from FDA notices of approvals, for example.
Organic Constant Currency Revenue Growth (Q4 2025): 5.4%US Business Growth (Q4 2025): 5.7% on an organic constant currency basisInternational Revenue Growth (Q
Zimmer Biomet Holdings, Inc. (ZBH) Q4 2025 Earnings Call Transcript
Zimmer Biomet beats Q4 earnings and revenue estimates, with sales up 10.9% and shares rising 1.4% pre-market despite margin contraction.
The headline numbers for Zimmer (ZBH) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zimmer Biomet (ZBH) came out with quarterly earnings of $2.42 per share, beating the Zacks Consensus Estimate of $2.38 per share. This compares to earnings of $2.31 per share a year ago.
Zimmer Biomet on Tuesday beat Wall Street estimates for fourth-quarter profit and revenue as the company capitalized on steady demand for its devices used in orthopedic procedures.
Fourth quarter net sales of $2.244 billion increased 10.9% on a reported basis, 9.2% on a constant currency1 basis and 5.4% on an organic constant currency1 basis Fourth quarter diluted earnings per share were $0.70, a decrease of 41.7%; adjusted1 diluted earnings per share were $2.42, an increase of 4.8% Full-year net sales of $8.232 billion increased 7.2% on a reported basis, 6.4% on a constant currency1 basis and 3.9% on an organic constant currency1 basis Full-year diluted earnings per share were $3.55, a decrease of 19.9%; adjusted1 diluted earnings per share were $8.20, an increase of 2.5% Company provides full-year 2026 financial guidance WARSAW, Ind., Feb. 10, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter and year ended December 31, 2025.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH - Get Free Report) has been assigned a consensus rating of "Hold" from the twenty-one research firms that are covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating, eight have given a buy rating and one has
Evaluate the expected performance of Zimmer (ZBH) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Partner Reed Kathrein Scrutinizing ZBH's "High Confidence" Assurances After 15% Stock Collapse and Reduced Revenue Guidance SAN FRANCISCO, Feb. 4, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (NYSE: ZBH) following a series of disclosures that calls into question the reasonable basis for the company's previously expressed "high confidence" in its 2025 revenue targets. The firm urges investors who suffered significant losses to submit your ZBH losses now and visit Hagens Berman's case page to view our latest investigation summary: www.hbsslaw.com/cases/zimmer-biomet-holdings-inc-zbh-investigation The investigation focuses on whether Zimmer Biomet senior management may have misled investors regarding the stability of its international business.
ZBH is set to report Q4 on Feb. 10, with revenues seen at $2.20B and EPS at $2.38 as hips, knees, robotics and S.E.T. drive growth estimates.
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Partner Reed Kathrein Scrutinizing ZBH's "High Confidence" Assurances After 15% Stock Collapse and Reduced Revenue Guidance SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (NYSE: ZBH) following a series of disclosures that calls into question the reasonable basis for the company's previously expressed “high confidence” in its 2025 revenue targets. The firm urges investors who suffered significant losses to submit your ZBH losses now and visit Hagens Berman's case page to view our latest investigation summary: www.hbsslaw.com/cases/zimmer-biomet-holdings-inc-zbh-investigation The investigation focuses on whether Zimmer Biomet senior management may have misled investors regarding the stability of its international business.
Partner Reed Kathrein Scrutinizing ZBH's "High Confidence" Assurances After 15% Stock Collapse and Reduced Revenue Guidance SAN FRANCISCO, Jan. 27, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (NYSE: ZBH) following a series of disclosures that calls into question the reasonable basis for the company's previously expressed "high confidence" in its 2025 revenue targets. The firm urges investors who suffered significant losses to submit your ZBH losses now and visit Hagens Berman's case page to view our latest investigation summary: www.hbsslaw.com/cases/zimmer-biomet-holdings-inc-zbh-investigation The investigation focuses on whether Zimmer Biomet senior management may have misled investors regarding the stability of its international business.